Xenon Pharmaceuticals Launches $500M Share Offering with $75M Option
Xenon Pharmaceuticals plans an underwritten public offering of $500 million in common shares and granted underwriters a 30-day option for an extra $75 million at the offering price. The offering uses its existing shelf registration and remains subject to market and other conditions with no guaranteed completion.
1. Offering Terms
Xenon Pharmaceuticals is offering $500 million of its common shares in an underwritten public offering, with all shares sold by the company at the public offering price less underwriting discounts and commissions.
2. Underwriter Option
Xenon granted underwriters a 30-day option to purchase up to $75 million of additional common shares at the same offering price.
3. Shelf Registration and Process
The offering is being made under Xenon’s existing shelf registration statement effective August 2024, with a preliminary prospectus supplement to be filed before any sale.
4. Market Conditions and Risks
Completion of the offering is subject to market and other conditions, with no assurance of closing and potential risks from economic or geopolitical factors.